Diagonal Bio

“The decision to change marketplace was based on the evaluation that the move to NGM will result in lower costs and possibilities for us to allocate more capital to marketing and sales, which is our main focus. I look forward to the journey ahead on NGM.” – Karin Wehlin, CEO of Diagonal Bio AB (publ)

Diagonal Bio announced the intention to change marketplace from Nasdaq First North Growth Market to NGM Nordic SME on 3 March 2025 and received a conditional approval from NGM on 4 March 2025. The first day of trading on NGM is today, 19 March 2025.

For additional information about Diagonal Bio, please contact:
Karin Wehlin, CEO

Phone: +46 70 305 24 88

E-mail: kw@diagonalbio.com

About Diagonal Bio

Diagonal Bio AB was founded in 2020 and is a Swedish biotechnology company with headquarters and offices in Lund. The Company develops the PANVIRAL® platform to detect and diagnose small sections of pathogen genomes, for example viruses, bacteria and fungi. The Company was founded with the goal of reducing human suffering by revolutionising global diagnostics of pathogen-borne diseases with proprietary technology. Diagonal Bio's patented technology can also be used for the less regulated market segments via LAMPlify®.